RacGAP1 is a novel downstream effector of E2F7-dependent resistance to doxorubicin and is prognostic for overall survival in squamous cell carcinoma

Article

Abstract: We have previously shown that E2F7 contributes to drug resistance in head and neck squamous cell car

Palabras claves:

Autores:

Boros S., Dantzic D.D.E., De Long L.M., Dzienis M., Gannon O.M., Hazar-Rethinam M., Mukhopadhyay P., Natalia Sáenz-Ponce, Saunders N.A., Simpson F., Vargas A.C.

Fuentes:

scopus